$16.04
-3.0%BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Chief Business Officer & Therapeutic Area Head of Brain Aging
Chief Financial Officer
Chief Medical Officer & Executive Vice President of Research
Compensation
$673,988
Chief Strategy Officer
Co-Founder, Chief Executive Officer, President, Treasurer, Secretary & Director
Compensation
$744,392
Co-Founder, Chief Operating Officer & Director
Compensation
$632,837
Senior Vice President of People
Senior Vice President of Regulatory Affairs
Senior Vice President of Research
Senior Vice President of Translational Aging Biology
During the last 12 months, insiders have purchased $583K and sold $1.63M worth of BIOA shares, resulting in $1.04M of net selling activity.
0
0.00
8.8K
157.08K
-157K
-$157K
0
0.00
49.3K
767.12K
-767K
-$767K
0
0.00
68.9K
701.91K
-702K
-$702K
132.0K
583.44K
0
0.00
+583K
+$583K
Enright Patrick G
Director
$98K
Garnier Jean Pierre
Director
$98K
Healy James
Director
$98K
Davidson Michael H.
Director
$98K
Hemrajani Rekha
Director
$98K
Rubin Paul D
Officer: Chief Medical Officer
$1.46M
Goldstein Dov A Md
Officer: Chief Financial Officer
$165K
Negative insider sentiment with $1.04M net selling. Selling notably exceeds buying, warranting closer scrutiny of company fundamentals.
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider buyers vs. 2 sellers. Broad-based buying across management team suggests widespread confidence.
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
BIOA - Filing history and reports
No SEC filings available for BIOA
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.